Sign In
Buy RPTX
$2.65
+0 (+0%)
At Close: Apr 24, 2026
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
11:19am, Wednesday, 11'th Oct 2023
Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy
Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks
11:17am, Monday, 09'th Oct 2023
The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
06:01am, Wednesday, 20'th Sep 2023
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
02:54pm, Wednesday, 16'th Aug 2023
Cathie Wood's ARK Genomic Revolution ETF is a top shareholder of Repare Therapeutics. Wood, along with several Wall Street analysts, hold an overtly bullish view on the biotech's growth prospects.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
08:37pm, Tuesday, 09'th May 2023
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.83 per share a year ago.
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%
11:26am, Wednesday, 03'rd May 2023
The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
09:50pm, Tuesday, 28'th Feb 2023
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s
Cathie Wood has been building stakes in two little-known stocks
01:27pm, Thursday, 09'th Feb 2023
Cathie Wood – the billionaire investor who recently called her flagship fund “the new Nasdaq” has been loading up on shares of the following two small-cap stocks in recent days. Velo3D Inc (NYSE
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
11:17am, Friday, 02'nd Dec 2022
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates
06:48pm, Wednesday, 09'th Nov 2022
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s
Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
09:10am, Wednesday, 07'th Sep 2022
Repare Therapeutics' shares have lost roughly half their value over the past year. Roche's deal for ATR inhibitor camonsertib validated the company's SNIPRx and STEP2 platform technologies, a unique t
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
08:18pm, Thursday, 04'th Aug 2022
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Biotech ETF Tops in June: 5 Stocks That Outperform
02:52pm, Thursday, 30'th Jun 2022
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar
